新闻发布

09.09.2019 | Launch of the FLEXcyte 96 – pushing the boundaries of cardiac safety screening

MUNICH, GERMANY, 09. September 2019: Nanion is pleased to announce the launch of the FLEXcyte 96 technology for cardiac contraction force measurements. Improving patient safety and reducing animal tests while saving time and money by replacing unnecessary in vivo experiments is the aim of this novel assay technology. The FLEXcyte 96 has been developed in cooperation with innoVitro GmbH.

The FLEXcyte 96 utilizes biomimetic substrates to culture and study hiPSC-CMs under physiological mechanical conditions, allowing the cells to react in a mature manner to pharmacological compounds without the need for additional stimulation. The technology will be available as an add-on to the CardioExcyte 96 platform from Nanion Technologies.

Read the full press release here.

Visit the FLEXcyte 96 product page here.

返回总览

 

New Genedata Screener®APC Functionality and Integration with Nanion SyncroPatch 384PE at SLAS2017

We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies).

You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.